No Data
Biomea Fusion Reports New Study Data From Two Preclinical Rat Models of Diabetes
11:59 AM EDT, 09/22/2022 (MT Newswires) -- Biomea Fusion (BMEA) said Thursday that new study data show that its drug BMF-219 is able to improve pancreatic beta cell area and function in two preclinica
Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes
Treatment with BMF-219 led to an increase in beta cell mass in ex-vivo experiments with human donor isletsBMF-219 showed improved pancreatic beta-cell function and beta cell area, insulin sensitivity,
Biomea Fusion, Inc.'s Stock Is Down 15%, but Insiders Still Have About US$26k in Profit After Buying Earlier This Year
Insiders who purchased Biomea Fusion, Inc. (NASDAQ:BMEA) shares in the past 12 months are unlikely to be deeply impacted by the stock's 15% decline over the past week. Reason being, despite the recen
H.C. Wainwright Keeps Their Buy Rating on Biomea Fusion (BMEA)
Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219's Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes
Biomea Fusion, Inc. (NASDAQ:BMEA) Sees Significant Decrease in Short Interest
Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) was the recipient of a large decline in short interest in August. As of August 15th, there was short interest totalling 353,000 shares, a decline of 21
Biomea Fusion, Inc. (NASDAQ:BMEA) Short Interest Update
Biomea Fusion, Inc. (NASDAQ:BMEA – Get Rating) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 353,000 shares
Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate
Biomea Fusion Inc (NASDAQ:BMEA) announced the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting. The first presentation covered preclinical data from BMF-219 i
H.C. Wainwright Remains a Buy on Biomea Fusion (BMEA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biomea Fusion (BMEA – Research Report) today and set a price target of $16.00. The company's shares opened today at $12.79. Accordin
How Is The Market Feeling About Biomea Fusion?
 Biomea Fusion's (NASDAQ:BMEA) short percent of float has fallen 17.37% since its last report. The company recently reported that it has 451 thousand shares sold short, which is 1.95% of all regular
Loading...
